ClinicalTrials.gg
Active, not recruitingNCT07011667Updated Sep 30, 2026

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

A Phase 3 interventional study of CagriSema (Cagrilintide B and Semaglutide I) and Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) in Obesity, sponsored by Novo Nordisk A/S. Active, not recruiting at 47 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Updated Sep 30, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
609
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing cagrilintide in Obesity — 9 open to participants now, 15 under way, 9 of them phase 3. cagrilintide · Obesity.

Enrollment
8th of 36
609 · median 154
Started
2025
with 5 others
Phase 3
15 of 36
4 open now
Primary completion
2027-03
later than 1 of 14 live
Registered
23rd of 36
by date
Lead sponsor
36 of 36
Novo Nordisk A/S

Among the 36 studies testing cagrilintide in Obesity, this one is the 8th largest by enrollment, is one of 6 that started in 2025, is one of 15 in phase 3, reaches primary completion later than 1 of the 14 other live ones, and was the 23rd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 36 studies testing cagrilintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About cagrilintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cagrilintide in Obesity, or all of them as a file.
02

Study summary

This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get CagriSema (a study medicine) or placebo (a dummy medicine that looks like CagriSema but has no active ingredient). Which treatment participants get is decided by chance. Participants are two times more likely to get CagriSema than placebo. If participants get CagriSema in the main study, participants will continue on CagriSema in the extension study. Which dose of CagriSema participants will continue on is decided by chance. If participants get placebo in the main study, participants will get CagriSema in the extension study. Participants will take one injection of study medicine once a week. The study will last for about 3 years and 3 months.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

key Inclusion Criteria:

  • Male or female (sex at birth).
  • Age 18 years or above at the time of signing the .
  • ≥ 30.0 kilogram per square meter (kg/m\^2) at screening.
  • Participant has a wish to lose at least 25% of body weight within 80 weeks from randomisation.

key Exclusion Criteria:

  • (HbA1c) ≥ 6.5% (48 millimole per mole [mmol/mol]) as measured by the central laboratory at screening.
  • History of type 1 or type 2 diabetes.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
609 participants (actual)

Study arms

  • Experimental
    CagriSema

    Participants will receive CagriSema subcutaneously once weekly in a dose escalation manner (dose increases every 4 weeks) for up to 16 weeks followed by CagriSema maintenance dose subcutaneously once weekly for 64 weeks in the main phase of the study. Participants randomised to this arm will be included in the extension phase to receive 1 of the 3 dose levels of CagriSema for 80 weeks.

    Drug: CagriSema (Cagrilintide B and Semaglutide I)

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to CagriSema subcutaneously once weekly for 80 weeks in the main phase of the study. Participants randomised to this arm will be included in the extension phase to receive CagriSema with flexible dose escalation for 80 weeks.

    Drug: CagriSema (Cagrilintide B and Semaglutide I) · Drug: Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)

Interventions

  • DrugCagriSema (Cagrilintide B and Semaglutide I)

    Drug page: Cagrilintide

    CagriSema (Cagrilintide B and Semaglutide I) will be administered subcutaneously using DV3384 pen-injector.

  • DrugPlacebo matched to CagriSema (Cagrilintide B and Semaglutide I)

    Placebo matched to Cagrilintide B and placebo matched to Semaglutide I will be administered subcutaneously using DV3384 pen-injector.

This study also gives Semaglutide. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Relative change in body weight

    Measured as percentage change.

    Time frame: From baseline (week 0) to week 80

Secondary outcomes

  1. Relative change in body weight in women

    Measured as percentage change.

    Time frame: From baseline (week 0) to week 80

  2. Number of participants who achieve greater than or equals (≥) 20% weight reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to week 80

  3. Number of participants who achieve ≥ 25% weight reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to week 80

  4. Number of participants who achieve ≥ 30% weight reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to week 80

  5. Number of participants who achieve BMI < 30 kg/m^2

    Measured as count of participants.

    Time frame: From baseline (week 0) to week 80

  6. Number of participants who achieve normal body mass index (BMI) (18.5 kilograms per meter square (kg/m^2) less than or equal to (≤ ) BMI < 25 kg/m^2)

    Measured as count of participants.

    Time frame: From baseline (week 0) to week 80

  7. Change in waist circumference

    Measured as centimeter (cm).

    Time frame: From baseline (week 0) to week 80

  8. Change in systolic blood pressure

    Measured as millimeters of mercury (mmHg).

    Time frame: From baseline (week 0) to week 80

  9. Ratio to baseline in C-reactive protein (CRP)

    Measured as ratio.

    Time frame: From baseline (week 0) to week 80

  10. Ratio to baseline in lipids: non-high density lipoprotein (HDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 80

  11. Ratio to baseline in lipids: triglycerides

    Measured as ratio.

    Time frame: From baseline (week 0) to week 80

  12. Ratio to baseline in lipids: HDL

    Measured as ratio.

    Time frame: From baseline (week 0) to week 80

  13. Change in impact of weight on quality of life-lite for clinical trials (IWQOL-Lite-CT) physical function score

    Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Physical function score ranges from 0 to 100, with higher scores indicating better levels of functioning.

    Time frame: From baseline (week 0) to week 80

  14. Change in short form (SF)-36v2 physical function

    Measured as score on a scale. The SF-36v2 acute measures health-related quality of life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 United States general population has a mean of 50 and a standard deviation of 10. Physical functioning score ranges from 19.0-57.6, with higher scores indicating better functional health and well-being.

    Time frame: From baseline (week 0) to week 80

  15. Change in IWQOL-Lite-CT physical function for subgroup with poor physical functioning at baseline (according to patient global impression of status [PGI-S])

    Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Physical function score ranges from 0 to 100, with higher scores indicating better levels of functioning. PGI-S at baseline is used to define the subgroup with "poor" physical function in IWQOL-Lite-CT.

    Time frame: From baseline (week 0) to week 80

  16. Change in SF-36v2 physical function for subgroup with poor physical functioning at baseline (according to PGI-S)

    Measured as score on a scale. SF-36v2 acute measures HRQOL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 United States general population has a mean of 50 and a standard deviation of 10. Physical functioning score ranges from 19.0-57.6, with higher scores indicating better functional health and well-being. PGI-S at baseline is used to define the subgroup with "poor" physical function in SF-36V2.

    Time frame: From baseline (week 0) to week 80

  17. Number of participants who achieve ≥ 5% weight reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to week 80

  18. Number of participants who achieve ≥ 10% weight reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to week 80

  19. Number of participants who achieve ≥ 15% weight reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to week 80

  20. Change in waist to height ratio

    Measured as ratio.

    Time frame: From baseline (week 0) to week 80

  21. Change in waist to hip ratio

    Measured as ratio.

    Time frame: From baseline (week 0) to week 80

  22. Number of participants with reduction in weight category

    Measured as count of participants. Reduction in weight categories: underweight, BMI \< 18.5 kg/m\^2; normal weight 18.5 kg/m\^2 ≤ BMI \< 25 kg/m\^2; overweight 25 kg/m\^2 ≤ BMI \< 30 kg/m\^2; obesity class I 30 kg/m\^2 ≤ BMI \< 35 kg/m\^2; obesity class II 35 kg/m\^2 ≤ BMI \< 40 kg/m\^2; obesity class III BMI ≥ 40 kg/m\^2.

    Time frame: From baseline (week 0) to week 80

  23. Change in diastolic blood pressure

    Measured as mmHg.

    Time frame: From baseline (week 0) to week 80

  24. Ratio to baseline in lipids: total cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 80

  25. Ratio to baseline in lipids: low-density lipoprotein (LDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 80

  26. Ratio to baseline in lipids: very low-density lipoprotein (VLDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to week 80

  27. Ratio to baseline in lipids: free fatty acids

    Measured as ratio.

    Time frame: From baseline (week 0) to week 80

  28. Change in control of eating questionnaire (CoEQ): craving control score

    Measured as score on a scale. CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the craving control subscale, the subscale score is reversed so that a higher score represents a greater level of craving control.

    Time frame: From baseline (week 0) to week 80

  29. Change in CoEQ: positive mood score

    Measured as score on a scale. CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the Positive Mood subscale, item 6 'How anxious have you felt?' is reversed.

    Time frame: From baseline (week 0) to week 80

  30. Change in CoEQ: craving for sweets score

    Measured as score on a scale. CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the craving sweets food subscale, higher score represents a greater level of craving.

    Time frame: From baseline (week 0) to week 80

  31. Change in CoEQ: craving for savoury score

    Measured as score on a scale. CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the craving savoury food subscale, higher score represents a greater level of craving.

    Time frame: From baseline (week 0) to week 80

  32. Change in CoEQ: hunger score

    Measured as score on a scale. CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the hunger subscale, higher score represents a greater level of craving.

    Time frame: From baseline (week 0) to week 80

  33. Change in CoEQ: satiety score

    Measured as score points. CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the satiety subscale, higher score represents a greater level of craving.

    Time frame: From baseline (week 0) to week 80

  34. Change in IWQOL-Lite-CT: physical score

    Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Physical score ranges from 0 to 100, with higher scores indicating better levels of functioning.

    Time frame: From baseline (week 0) to week 80

  35. Change in IWQOL-Lite-CT: psychosocial score

    Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Psychosocial score ranges from 0 to 100, with higher scores indicating better levels of functioning.

    Time frame: From baseline (week 0) to week 80

  36. Change in IWQOL-Lite-CT: total score

    Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Total score ranges from 0 to 100, with higher scores indicating better levels of functioning.

    Time frame: From baseline (week 0) to week 80

  37. Change in SF-36v2 health survey acute: physical component summary score

    Measured as score on a scale. The SF-36v2 acute measures HRQOL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 United States general population has a mean of 50 and a standard deviation of 10. The physical component summary score ranges from 6.1-79.7, with higher scores indicating better functional health and well-being.

    Time frame: From baseline (week 0) to week 80

  38. Change in SF-36v2 health survey acute: mental component summary

    Measured as score on a scale. The SF-36v2 acute measures HRQOL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 United States general population has a mean of 50 and a standard deviation of 10. The mental component summary score ranges from -3.8-78.7, with higher scores indicating better functional health and well-being.

    Time frame: From baseline (week 0) to week 80

  39. Number of treatment emergent adverse events (TEAEs)

    Measured as count of events.

    Time frame: From baseline (week 0) to week 80

  40. Number of treatment emergent serious adverse events (TESAEs)

    Measured as count of events.

    Time frame: From baseline (week 0) to week 80

07

Study locations

47 sites
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Mar 2027, 20 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 20 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2025
First posted
Jun 9, 2025
StartActual
Jun 3, 2025
Primary completionEst.
Mar 1, 2027
CompletionEst.
Oct 17, 2028
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Consano Clinical Research, LLC · Shavano Park, United States
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    1 site added
    Show site
    • Consano Clinical Research, LLC · Shavano Park, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07011667
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 9, 2025
Start date
Jun 3, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Oct 17, 2028 (estimated)
Last update
Sep 30, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion